Articles related to ANTIPSYCHOTICS

Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.

The Johns Hopkins Clozapine Consultation Clinic is addressing the critical underutilization of clozapine in treatment-resistant schizophrenia, providing essential support and education for healthcare providers in navigating its benefits and risks.

LYN-005 represents a breakthrough in schizophrenia management, showing promise in maintaining therapeutic levels and symptom control with just once-weekly dosing.

The JEWEL study has demonstrated that lurasidone treatment in patients with schizophrenia results in significant improvements in social functioning, with notable progress observed from the early stages of treatment and sustained benefits over a 12-week extension period.

In a phase 3 study, iloperidone demonstrated a significant improvement in treating bipolar mania, marked by a reduction in the Young Mania Rating Scale (YMRS) scores.

Explore the latest advances in schizophrenia research and understand how TAAR1 agonism could potentially change the treatment paradigm. Join us in this educational journey.